Meta-analysis of 13 retrospective studies (7206 patients) of early HER2-positive breast cancer given anti-HER2 neoadjuvant therapy: pCR was higher in IHC 3+ than 2+/ISH+ tumours (55.1% vs 21.6%; OR 5.38); 3-year invasive DFS did not differ significantly.
Meta-analysisn = 7,206
Yucel et al. Comparison of the pathological complete response between immunohistochemistry HER2 (3 + ) and HER2 (2 + )/ISH + Early-stage breast cancer: a systematic review and meta-analysis